Clinical trials in Zaragoza – page 3

549 clinical trials in Zaragoza, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Zaragoza at a glance

549

clinical trials

Research sites3

Quick filters

549 trials in Zaragoza

Open in trial search

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Neoplasm malignant

Recruiting

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Non-small cell lung cancer

Recruiting

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Divarasib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Transitional cell carcinoma+1

Recruiting

Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma

Registered drugNo placebo

Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Summit Therapeutics Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Asthma

Recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Beclometasone Dipropionate
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Gastrooesophageal cancer+6

Recruiting

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Glatiramer Acetate
Sponsor:Genmab A/S

Contact Research Centre

Dermatitis atopic

Recruiting

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Sodium Chloride

Contact Research Centre

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Dementia Alzheimer's type

Recruiting

A study of SAR448851 with florquinitau (18F) to assess safety and effectiveness in early Alzheimer’s disease

Investigational

A study of SAR448851 with florquinitau (18F) to assess safety and effectiveness in early Alzheimer’s disease

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Florquinitau (18F)
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Colitis ulcerative

Recruiting

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Golimumab
Sponsor:Janssen Cilag International

Contact Research Centre

Type 2 diabetes mellitus

Recruiting

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Zaragoza

What the registry says about research in the country

01 Oncology & Hematology

Innovative research focusing on advanced cancer treatments and blood disorders, including studies of new therapies for lung cancer, pancreatic adenocarcinoma, and various hematologic malignancies.

Non-small cell lung cancer treatments
Chronic lymphocytic leukemia therapies
Soft tissue sarcoma management

Multiple trials evaluating combination therapies and novel treatment approaches for both solid tumors and blood cancers.

02 Autoimmune & Inflammatory Conditions

Research into treatments for various inflammatory and autoimmune disorders, with emphasis on chronic conditions affecting quality of life.

Plaque psoriasis treatments
Crohn's disease management
Thyroid eye disease therapies

Studies focusing on innovative biological therapies and targeted treatments for inflammatory conditions.

03 Cardiovascular & Metabolic Disorders

Studies addressing critical cardiovascular health challenges and metabolic conditions, including innovative approaches to stroke treatment and lipid management.

Acute cerebral ischemic stroke
Hypertriglyceridemia treatments
Cardiovascular disease prevention

Focus on developing new therapeutic options for both acute and chronic cardiovascular conditions.

Back to Spain All countries